A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks

NCT07752407 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Symptomatic Non-erosive Gastroesophageal Reflux Disease

Interventions

DRUG: Vonoprazan
DRUG: Placebo

Sponsor

Phathom Pharmaceuticals, Inc.